Compounding pharmacies for weight-loss drugs are booming. Should you trust them?
TIME reports on the growth of compounding pharmacies supplying GLP-1 weight-loss drugs, often through telehealth sites. It follows a 72-year-old patient who says she could barely function after her compounded tirzepatide supplier changed. A Gallup poll cited estimates 5 million people in the U.S. use compounded GLP-1s. The story contrasts lighter oversight of 503A pharmacies with stricter 503B rules, and notes Eli Lilly's objections.
Why it matters: Relevant to adults weighing GLP-1 weight-loss medication through telehealth or compounded sources, and to clinicians who field patient questions about where these drugs come from.
A summary of another publisher's reporting, written with AI and checked automatically against the story. The reporting belongs to time.com. October 7, 2026.